320 related articles for article (PubMed ID: 34670829)
21. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
Davidson BA; Broadwater G; Crim A; Boccacio R; Bixel K; Backes F; Previs RA; Salinaro J; Salani R; Moore K; Secord AA
Gynecol Oncol; 2019 Mar; 152(3):554-559. PubMed ID: 30558972
[TBL] [Abstract][Full Text] [Related]
22. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
24. Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
Jorgensen K; Melamed A; Wu CF; Nitecki R; Pareja R; Fagotti A; Schorge JO; Ramirez PT; Rauh-Hain JA
Gynecol Oncol; 2023 May; 172():130-137. PubMed ID: 36977622
[TBL] [Abstract][Full Text] [Related]
25. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
Kim JS; Liang MI; Prendergast EN; Alldredge J; Datta A; Hurteau JA; Kirschner CV; Rodriguez G; Vogel TJ; Brooks RA; Cass I; Cohen JG; Penner KR; Wang CE; Diaz Moore ES
Int J Gynecol Cancer; 2019 Sep; 29(7):1156-1163. PubMed ID: 31352365
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
[TBL] [Abstract][Full Text] [Related]
28. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
29. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E
Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273
[TBL] [Abstract][Full Text] [Related]
30. Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer.
Angeles MA; Migliorelli F; Del M; Martínez-Gómez C; Daix M; Bétrian S; Gabiache E; Balagué G; Leclerc S; Mery E; Gladieff L; Ferron G; Martinez A
Arch Gynecol Obstet; 2021 May; 303(5):1295-1304. PubMed ID: 33389113
[TBL] [Abstract][Full Text] [Related]
31. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
[TBL] [Abstract][Full Text] [Related]
32. [Epithelial ovarian cancers and minimally invasive cytoreductive surgery after neoadjuvant chemotherapy: A systematic review].
Achen G; Koual M; Bentivegna E; Fournier L; Nguyen Xuan HT; Delanoy N; Bats AS; Azaïs H
Gynecol Obstet Fertil Senol; 2021 Oct; 49(10):736-743. PubMed ID: 33636412
[TBL] [Abstract][Full Text] [Related]
33. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis.
Cardenas-Goicoechea J; Wang Y; McGorray S; Saleem MD; Carbajal Mamani SL; Pomputius AF; Markham MJ; Castagno JC
J Robot Surg; 2019 Feb; 13(1):23-33. PubMed ID: 29992404
[TBL] [Abstract][Full Text] [Related]
34. Laparoscopic Management of Ovarian Cancer Patients With Localized Carcinomatosis and Lymph Node Metastases: Results of a Retrospective Multi-institutional Series.
Gallotta V; Ghezzi F; Vizza E; Fagotti A; Ceccaroni M; Fanfani F; Chiantera V; Ercoli A; Rossitto C; Conte C; Uccella S; Corrado G; Scambia G; Ferrandina G
J Minim Invasive Gynecol; 2016; 23(4):590-6. PubMed ID: 26872630
[TBL] [Abstract][Full Text] [Related]
35. Single-port or Classic Laparoscopy Compared With Laparotomy to Assess the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer.
Bresson L; Allard-Duclercq C; Narducci F; Tresch E; Lesoin A; Ahmeidi A; Leblanc E
J Minim Invasive Gynecol; 2016; 23(5):825-32. PubMed ID: 27068278
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer.
Paik ES; Lee YY; Kim TJ; Choi CH; Lee JW; Kim BG; Bae DS
J Gynecol Oncol; 2016 May; 27(3):e24. PubMed ID: 27029745
[TBL] [Abstract][Full Text] [Related]
37. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
[TBL] [Abstract][Full Text] [Related]
38. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
[TBL] [Abstract][Full Text] [Related]
39. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
40. Change of Fagotti score is associated with outcome after neoadjuvant chemotherapy for ovarian cancer.
Saner FAM; Ruggeri G; Siegenthaler F; Wampfler J; Imboden S; Mueller MD
Int J Gynecol Cancer; 2023 Oct; 33(10):1595-1601. PubMed ID: 37567597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
